ClinConnect ClinConnect Logo
Search / Trial NCT03866382

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Launched by NATIONAL CANCER INSTITUTE (NCI) · Mar 6, 2019

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is investigating how well three medications—cabozantinib, nivolumab, and ipilimumab—work together to treat patients with rare genitourinary tumors that have spread to other parts of the body. Cabozantinib is a targeted therapy that may help stop the growth of cancer cells, while nivolumab and ipilimumab are types of immunotherapy that help the body’s immune system fight cancer. The study aims to see if this combination is more effective than using any of these drugs alone for patients who have limited treatment options.

To participate in this trial, patients must be at least 18 years old and have specific types of metastatic genitourinary cancers, such as certain bladder or kidney cancers. They should have measurable disease confirmed by imaging tests and may have received up to two previous cancer treatments. Participants can expect to take the medications orally and will be monitored closely for side effects and treatment response. It's important to note that women who are pregnant or breastfeeding cannot participate, and there are strict eligibility criteria to ensure patient safety. If you think this trial might be right for you or a loved one, please discuss it with your healthcare provider.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Metastatic disease defined as new or progressive lesions on cross-sectional imaging or bone scan. Patients must have at least:
  • One measurable site of disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
  • One bone lesion on bone scan (tec99 or sodium fluoride \[NaF\] PET/CT, CT or MRI) for the bone-only cohort.
  • * Histologically confirmed diagnosis of one of the following metastatic cohorts:
  • Small cell/ neuroendocrine carcinoma of the bladder (Cohort A)- All urothelial carcinomas with any amount of neuroendocrine differentiation (including small cell differentiation) will be included. If the tumor is purely neuroendocrine, metastasis from another site of origin should be clinically excluded
  • Adenocarcinoma of the bladder, or urachal adenocarcinoma, or bladder/urethra clear cell adenocarcinoma (Cohort B) - must be pure (per World Health Organization \[WHO\] definition), (i.e. urothelial carcinoma with glandular differentiation is not considered a pure adenocarcinoma
  • Squamous cell carcinoma of the bladder (Cohort C) - must be pure (i.e. urothelial carcinoma with squamous differentiation is not considered a pure squamous cell carcinoma)
  • Plasmacytoid urothelial carcinoma (Cohort D) - Tumor should show predominantly \> or equal \~ 50% plasmacytoid histology (including all types of discohesive growth, such as tumors with signet-ring and/or rhabdoid features as well)
  • Any penile cancer (Cohort E)
  • Sarcomatoid renal cell carcinoma (Cohort F) - Tumor should be predominantly sarcomatoid \~ 50% (including rhabdoid differentiation) is also unclassified renal cell carcinomas (RCCs): all (assuming they are high grade with metastasis) malignant angiomyolipomas are allowed
  • Other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to (Cohort G) : Micropapillary (Tumor should show predominantly \> or equal 50% micropapillary architecture), giant cell, lipid-rich, clear cell and nested variants (Tumor should predominantly \> or equal 50% show these features), large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer (Only treatment-naïve primary small cell of prostate with any amount of small cell component allowed. Post-treatment small cell prostatic carcinomas are not allowed), Malignant testicular Sertoli or Leydig cell tumors, and papillary and chromophobe RCC
  • Note: Translocation positive renal cell carcinoma patients are eligible. However, AREN1721 should be considered before this trial
  • Sarcomatoid urothelial carcinoma (Cohort H) - Tumor should show predominantly \~ 50% sarcomatoid differentiation
  • Renal medullary carcinoma (Cohort I) - Per World Health Organization (WHO) definition, ideally confirmed with immunostains
  • Bone-only metastatic GU tumors (non-prostate) (Cohort J) - All genitourinary histologies, except prostate are eligible
  • Renal Collecting Duct Carcinoma (Cohort K) - Per WHO definition (medullary involvement, predominant tubular morphology, desmoplastic stromal reaction, high grade cytology, infiltrative growth pattern, and absence of other renal cell carcinoma subtype or urothelial carcinoma)
  • Urethra carcinoma (Cohort L) - May be of any histology but if urothelial carcinoma then must be isolated to the urethra and not have metachronous or synchronous urothelial carcinoma of the bladder
  • H\&E slides from diagnostic tumor tissue for retrospective central pathology review
  • Patients may have received up to 2 systemic anti-cancer treatments or be treatment naive. Patients with small cell carcinoma should have received a platinum-based combination regimen either as neoadjuvant, adjuvant or first-line treatment). Patients in the bone-only cohort may be urothelial carcinoma histology but must receive standard cisplatin-based chemotherapy (if cisplatin-eligible)
  • Age \>= 18 years
  • Patients must be able to swallow oral formulation of the tablets
  • Karnofsky performance status \>= 80%
  • Absolute neutrophil count (ANC) \>= 1,000/mcL
  • Platelet count \>= 75,000/mcL
  • Total bilirubin =\< 1.5 x upper limit of normal (ULN). For subjects with known Gilbert's disease or similar syndrome with slow conjugation of bilirubin, total bilirubin =\< 3.0 mg/dL
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3.0 x institutional upper limit of normal (ULN) (or =\< 5 x ULN for patients with liver metastases or Gilbert's disease)
  • Creatinine =\< 1.5 x upper limit of normal (ULN) OR creatinine clearance \>= 40 mL/min/1.73 m\^2 (calculated using the Chronic Kidney Disease Epidemiology \[CKD-EPI\] equation or Cockcroft-Gault formula) for patients with creatinine levels above institutional normal
  • Hemoglobin \>= 9 g/dL (transfusion of packed red blood cells \[PRBCs\] allowed)
  • Serum albumin \>= 3.2 g/dL
  • Lipase and amylase =\< 2.0 x ULN and no radiologic (on baseline anatomical imaging) or clinical evidence of pancreatitis
  • Prior treatment with MET or VEGFR inhibitors is allowed. However, prior cabozantinib will not be allowed. Also, patients that have received both prior MET or VEGF and prior PD-1/PD-L1/CTLA-4 (sequentially or in combination) are also not allowed
  • No prior treatment with any therapy on the PD-1/PD-L1 axis or anti- CTLA-4/CTLA-4 inhibitors with the exception of patients with "urothelial carcinoma" histology (cohorts D, H, J, L)
  • Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), no clinically significant drug-drug interactions are anticipated with the current HAART regimen, CD4 counts are greater than 350 and viral load is undetectable
  • Patients with rheumatoid arthritis and other rheumatologic arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication only and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies etc. are eligible but should be considered for rheumatologic evaluation for the presence of target organ involvement and potential need for systemic treatment
  • Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones or medications (e.g. thyroiditis managed with propylthiouracil \[PTU\] or methimazole) including physiologic oral corticosteroids are eligible
  • Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, and gastrointestinal (GI) obstruction, within 12 months are not eligible
  • Women of childbearing potential must have a negative pregnancy test =\< 7 days prior to registration
  • Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post menopause is defined as amenorrhea \>= 12 consecutive months. Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason
  • Pregnant women may not participate in this study because with cabozantinib, nivolumab, and ipilimumab have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cabozantinib, nivolumab, and ipilimumab, breastfeeding should be discontinued if the mother is treated with these agents
  • The patient has received no cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 2 weeks before the first dose of study treatment
  • * The patient has received no radiation therapy:
  • To the lungs and mediastinum or abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy
  • To brain metastasis within 3 weeks for whole-brain radiotherapy (WBXRT), and 2 weeks for stereotactic body radiation therapy (SBRT) before the first dose of study treatment
  • To the abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy
  • To any other site(s) within 2 weeks before the first dose of study treatment
  • The patient has received no radionuclide treatment within 6 weeks of the first dose of study treatment
  • The patient has received no prior treatment with a small molecule kinase inhibitor within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
  • The patient has received no prior treatment with hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment. Subjects receiving gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participate
  • The patient has not received any other type of investigational agent within 14 days before the first dose of study treatment
  • The patient must have recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =\< grade 1 from toxicity due to all prior therapies except alopecia, neuropathy and other non-clinically significant adverse events (AEs) defined as lab elevation with no associated symptoms or sequelae
  • The patient may not have active brain metastases or epidural disease. Patients with brain metastases previously treated with whole brain radiation or radiosurgery who are asymptomatic and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible. Neurosurgical resection of brain metastases or brain biopsy is permitted if completed at least 3 months before starting study treatment. Baseline brain imaging with contrast-enhanced CT or MRI scans for subjects with known brain metastases is required to confirm eligibility
  • No concomitant treatment with warfarin. Aspirin (up to 325 mg/day), thrombin or factor Xa inhibitors, low-dose warfarin (=\< 1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH) are permitted
  • No chronic concomitant treatment with strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's wort) or strong CYP3A4 inhibitors
  • Because the lists of these agents are constantly changing, it is important to regularly consult medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
  • * The patient has not experienced any of the following:
  • Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment
  • Hemoptysis of \>= 0.5 teaspoon (2.5 mL) of red blood per day within 1 months before the first dose of study treatment
  • Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
  • The patient has no tumor invading any major blood vessels
  • The patient has no evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib. Patients with rectal tumor masses are not eligible
  • * The patient has no uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
  • * Cardiovascular disorders including:
  • Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening.
  • Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) \> 150 mm Hg systolic, or \> 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment
  • The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) \> 500 ms within 28 days before randomization. Note: if initial QTcF is found to be \> 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =\< 500 ms, the subject meets eligibility in this regard
  • Any history of congenital long QT syndrome
  • * Any of the following within 6 months before registration of study treatment:
  • Unstable angina pectoris
  • Clinically-significant cardiac arrhythmias (patients with atrial fibrillation are eligible)
  • Stroke (including transient ischemic attack \[TIA\], or other ischemic event)
  • Myocardial infarction
  • Cardiomyopathy
  • * No significant gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:
  • * Any of the following that have not resolved within 28 days before the first dose of study treatment:
  • Active peptic ulcer disease
  • Acute diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or malabsorption syndrome
  • * None of the following within 2 years before the first dose of study treatment:
  • Abdominal fistula or genitourinary fistula
  • Gastrointestinal perforation
  • Bowel obstruction or gastric outlet obstruction
  • Intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 2 years before the first dose of study treatment
  • Disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement are not eligible
  • * No other clinically significant disorders such as:
  • Severe active infection requiring IV systemic treatment within 14 days before the first dose of study treatment
  • Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment
  • History of organ or allogeneic stem cell transplant
  • Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid-stimulating hormone \[TSH\], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)
  • * No history of major surgery as follows:
  • Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery
  • Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and mediport placement
  • Complete wound healing from prior surgery must be confirmed before the first dose of cabozantinib irrespective of the time from surgery
  • No history of severe hypersensitivity reaction to any monoclonal antibody
  • No evidence of active malignancy, requiring systemic treatment within 2 years of registration
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in study
  • No positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. If HBV sAG is positive, subsequent ribonucleic acid (RNA) polymerase chain reaction (PCR) must be negative
  • No patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include, but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease

About National Cancer Institute (Nci)

The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.

Locations

Chicago, Illinois, United States

Brooklyn, New York, United States

Charleston, South Carolina, United States

Bethesda, Maryland, United States

Buffalo, New York, United States

Saint Louis, Missouri, United States

Flint, Michigan, United States

Denver, Colorado, United States

Flint, Michigan, United States

Burnsville, Minnesota, United States

Edina, Minnesota, United States

Waconia, Minnesota, United States

Maywood, Illinois, United States

Peoria, Illinois, United States

New Orleans, Louisiana, United States

Detroit, Michigan, United States

Anchorage, Alaska, United States

Oklahoma City, Oklahoma, United States

Great Falls, Montana, United States

New York, New York, United States

Saint Paul, Minnesota, United States

Chanute, Kansas, United States

Dodge City, Kansas, United States

Newton, Kansas, United States

Wellington, Kansas, United States

Winfield, Kansas, United States

Jackson, Mississippi, United States

Bozeman, Montana, United States

Kalispell, Montana, United States

Delaware, Ohio, United States

Lancaster, Ohio, United States

Sheridan, Wyoming, United States

Chicago, Illinois, United States

Cincinnati, Ohio, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Oakland, California, United States

Mount Vernon, Illinois, United States

Salina, Kansas, United States

Chillicothe, Ohio, United States

Yakima, Washington, United States

Salina, Kansas, United States

Coon Rapids, Minnesota, United States

Renton, Washington, United States

Urbana, Illinois, United States

Wichita, Kansas, United States

Ann Arbor, Michigan, United States

Minneapolis, Minnesota, United States

Saint Paul, Minnesota, United States

Shakopee, Minnesota, United States

Willmar, Minnesota, United States

Council Bluffs, Iowa, United States

Dayton, Ohio, United States

Effingham, Illinois, United States

Independence, Kansas, United States

Lawrence, Kansas, United States

Saint Joseph, Missouri, United States

Greenville, Ohio, United States

Mount Vernon, Ohio, United States

Bethlehem, Pennsylvania, United States

Longmont, Colorado, United States

Springfield, Illinois, United States

Baltimore, Maryland, United States

Cincinnati, Ohio, United States

Portland, Oregon, United States

Springfield, Illinois, United States

Pittsburgh, Pennsylvania, United States

Minneapolis, Minnesota, United States

Rochester, New York, United States

Birmingham, Alabama, United States

Scottsdale, Arizona, United States

Tucson, Arizona, United States

Clovis, California, United States

Los Angeles, California, United States

Washington, District Of Columbia, United States

Atlanta, Georgia, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

New Orleans, Louisiana, United States

New Orleans, Louisiana, United States

Duluth, Minnesota, United States

Saint Louis, Missouri, United States

Kearney, Nebraska, United States

Omaha, Nebraska, United States

New York, New York, United States

New York, New York, United States

New York, New York, United States

Syracuse, New York, United States

Chapel Hill, North Carolina, United States

Columbus, Ohio, United States

Pittsburgh, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Knoxville, Tennessee, United States

Nashville, Tennessee, United States

Jacksonville, Florida, United States

Los Angeles, California, United States

Aurora, Illinois, United States

Lexington, Kentucky, United States

Columbus, Ohio, United States

Columbus, Ohio, United States

Kettering, Ohio, United States

Tulsa, Oklahoma, United States

Allentown, Pennsylvania, United States

Centralia, Washington, United States

Federal Way, Washington, United States

Lakewood, Washington, United States

Cape Girardeau, Missouri, United States

Aventura, Florida, United States

Oakland, California, United States

Martinez, California, United States

Coos Bay, Oregon, United States

Pueblo, Colorado, United States

New Orleans, Louisiana, United States

Fridley, Minnesota, United States

Robbinsdale, Minnesota, United States

Saint Louis Park, Minnesota, United States

Saint Louis, Missouri, United States

Omaha, Nebraska, United States

Lima, Ohio, United States

Portland, Oregon, United States

Omaha, Nebraska, United States

Omaha, Nebraska, United States

Milwaukee, Wisconsin, United States

Fort Lauderdale, Florida, United States

Dallas, Texas, United States

Orlando, Florida, United States

Detroit, Michigan, United States

Rochester, Minnesota, United States

Saint Louis, Missouri, United States

Las Vegas, Nevada, United States

Marshfield, Wisconsin, United States

Portland, Oregon, United States

Newark, Ohio, United States

Mcpherson, Kansas, United States

Reno, Nevada, United States

Miami Beach, Florida, United States

Decatur, Illinois, United States

Ottawa, Illinois, United States

Peoria, Illinois, United States

El Dorado, Kansas, United States

Kingman, Kansas, United States

Parsons, Kansas, United States

Pratt, Kansas, United States

Wichita, Kansas, United States

Helena, Montana, United States

Missoula, Montana, United States

Galesburg, Illinois, United States

Clive, Iowa, United States

Des Moines, Iowa, United States

Jackson, Michigan, United States

Lansing, Michigan, United States

Warren, Michigan, United States

Brainerd, Minnesota, United States

Duluth, Minnesota, United States

Duluth, Minnesota, United States

Lincoln, Nebraska, United States

Papillion, Nebraska, United States

Anchorage, Alaska, United States

Omaha, Nebraska, United States

Cape Girardeau, Missouri, United States

Peru, Illinois, United States

Des Moines, Iowa, United States

Pontiac, Michigan, United States

Maplewood, Minnesota, United States

Maplewood, Minnesota, United States

Stillwater, Minnesota, United States

Great Falls, Montana, United States

Findlay, Ohio, United States

Toledo, Ohio, United States

Bremerton, Washington, United States

Burbank, California, United States

Greenbrae, California, United States

Atlanta, Georgia, United States

Alton, Illinois, United States

Galesburg, Illinois, United States

Richmond, Indiana, United States

Ames, Iowa, United States

Pittsburg, Kansas, United States

Topeka, Kansas, United States

Wichita, Kansas, United States

Port Huron, Michigan, United States

Saginaw, Michigan, United States

Woodbury, Minnesota, United States

Joplin, Missouri, United States

Kansas City, Missouri, United States

Springfield, Missouri, United States

Springfield, Missouri, United States

Billings, Montana, United States

Missoula, Montana, United States

Reno, Nevada, United States

Boardman, Ohio, United States

Cincinnati, Ohio, United States

Dayton, Ohio, United States

Dayton, Ohio, United States

Franklin, Ohio, United States

Toledo, Ohio, United States

Troy, Ohio, United States

Warren, Ohio, United States

Youngstown, Ohio, United States

East Stroudsburg, Pennsylvania, United States

Tacoma, Washington, United States

Vancouver, Washington, United States

Minocqua, Wisconsin, United States

Oconomowoc, Wisconsin, United States

Rice Lake, Wisconsin, United States

Sheboygan, Wisconsin, United States

Waukesha, Wisconsin, United States

West Allis, Wisconsin, United States

Weston, Wisconsin, United States

Kettering, Ohio, United States

Emeryville, California, United States

Colorado Springs, Colorado, United States

Lakewood, Colorado, United States

Burlington, Massachusetts, United States

Columbus, Ohio, United States

Columbus, Ohio, United States

Marietta, Ohio, United States

Newark, Ohio, United States

Springfield, Ohio, United States

Westerville, Ohio, United States

Zanesville, Ohio, United States

Bellingham, Washington, United States

Seattle, Washington, United States

Seattle, Washington, United States

Livonia, Michigan, United States

Mansfield, Ohio, United States

Bremerton, Washington, United States

Kennewick, Washington, United States

Sedro Woolley, Washington, United States

Clackamas, Oregon, United States

Newberg, Oregon, United States

Oshkosh, Wisconsin, United States

Littleton, Colorado, United States

New Ulm, Minnesota, United States

Boise, Idaho, United States

Hendersonville, North Carolina, United States

Tucson, Arizona, United States

Las Vegas, Nevada, United States

Louisville, Kentucky, United States

Canton, Illinois, United States

Carthage, Illinois, United States

Eureka, Illinois, United States

Kewanee, Illinois, United States

Macomb, Illinois, United States

Peru, Illinois, United States

Princeton, Illinois, United States

Boise, Idaho, United States

Fargo, North Dakota, United States

Parker, Colorado, United States

Joplin, Missouri, United States

Lake Success, New York, United States

Walla Walla, Washington, United States

Grafton, Wisconsin, United States

Grand Island, Nebraska, United States

Fort Smith, Arkansas, United States

Post Falls, Idaho, United States

Bloomington, Illinois, United States

Pekin, Illinois, United States

Hays, Kansas, United States

Liberal, Kansas, United States

Fergus Falls, Minnesota, United States

Bolivar, Missouri, United States

Branson, Missouri, United States

Saint Louis, Missouri, United States

Lawton, Oklahoma, United States

Bend, Oregon, United States

Erie, Pennsylvania, United States

Franklin, Tennessee, United States

Poulsbo, Washington, United States

Burlington, Wisconsin, United States

Germantown, Wisconsin, United States

Green Bay, Wisconsin, United States

Kenosha, Wisconsin, United States

Marinette, Wisconsin, United States

Milwaukee, Wisconsin, United States

Racine, Wisconsin, United States

Summit, Wisconsin, United States

Two Rivers, Wisconsin, United States

Wauwatosa, Wisconsin, United States

Los Angeles, California, United States

Hot Springs, Arkansas, United States

Arroyo Grande, California, United States

Olathe, Kansas, United States

Jefferson City, Missouri, United States

Saint Louis, Missouri, United States

Omaha, Nebraska, United States

Oklahoma City, Oklahoma, United States

Erie, Pennsylvania, United States

Nashville, Tennessee, United States

Bryan, Texas, United States

Longview, Washington, United States

Dearborn, Michigan, United States

Tucson, Arizona, United States

Emeryville, California, United States

Atlanta, Georgia, United States

Fruitland, Idaho, United States

Meridian, Idaho, United States

Nampa, Idaho, United States

Twin Falls, Idaho, United States

Baton Rouge, Louisiana, United States

Lee's Summit, Missouri, United States

Rolla, Missouri, United States

Rolla, Missouri, United States

Columbus, Ohio, United States

Columbus, Ohio, United States

Portsmouth, Ohio, United States

Oregon City, Oregon, United States

Monroeville, Pennsylvania, United States

Natrona Heights, Pennsylvania, United States

Bellevue, Washington, United States

Burien, Washington, United States

Edmonds, Washington, United States

Everett, Washington, United States

Issaquah, Washington, United States

Lacey, Washington, United States

Eau Claire, Wisconsin, United States

New Richmond, Wisconsin, United States

Urbana, Illinois, United States

Springfield, Illinois, United States

Belpre, Ohio, United States

Columbus, Ohio, United States

Delaware, Ohio, United States

Brooklyn, New York, United States

Longmont, Colorado, United States

Las Vegas, Nevada, United States

Monroeville, Pennsylvania, United States

Springfield, Ohio, United States

Saint Peters, Missouri, United States

Greensburg, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Anchorage, Alaska, United States

Great Falls, Montana, United States

Caldwell, Idaho, United States

Coeur D'alene, Idaho, United States

Emmett, Idaho, United States

Meridian, Idaho, United States

Nampa, Idaho, United States

Sandpoint, Idaho, United States

Clive, Iowa, United States

West Des Moines, Iowa, United States

Garden City, Kansas, United States

Great Bend, Kansas, United States

Manhattan, Kansas, United States

Brighton, Michigan, United States

Canton, Michigan, United States

Caro, Michigan, United States

Chelsea, Michigan, United States

Clarkston, Michigan, United States

Clarkston, Michigan, United States

East China Township, Michigan, United States

Flint, Michigan, United States

Flint, Michigan, United States

Grosse Pointe Woods, Michigan, United States

Grosse Pointe Woods, Michigan, United States

Grosse Pointe Woods, Michigan, United States

Livonia, Michigan, United States

Macomb, Michigan, United States

Macomb, Michigan, United States

Marlette, Michigan, United States

Pontiac, Michigan, United States

Pontiac, Michigan, United States

Pontiac, Michigan, United States

Rochester Hills, Michigan, United States

Saginaw, Michigan, United States

Sterling Heights, Michigan, United States

Warren, Michigan, United States

Warren, Michigan, United States

Warren, Michigan, United States

Warren, Michigan, United States

West Branch, Michigan, United States

Ypsilanti, Michigan, United States

Minneapolis, Minnesota, United States

Anaconda, Montana, United States

Henderson, Nevada, United States

Henderson, Nevada, United States

Henderson, Nevada, United States

Henderson, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Centerville, Ohio, United States

Dublin, Ohio, United States

Grove City, Ohio, United States

Marion, Ohio, United States

West Chester, Ohio, United States

Baker City, Oregon, United States

Ontario, Oregon, United States

Cody, Wyoming, United States

Anchorage, Alaska, United States

Anchorage, Alaska, United States

Anchorage, Alaska, United States

Anchorage, Alaska, United States

Anchorage, Alaska, United States

Colorado Springs, Colorado, United States

Durango, Colorado, United States

Durango, Colorado, United States

Creston, Iowa, United States

Bardstown, Kentucky, United States

Corbin, Kentucky, United States

Lexington, Kentucky, United States

Lexington, Kentucky, United States

Louisville, Kentucky, United States

Shepherdsville, Kentucky, United States

Commack, New York, United States

Cincinnati, Ohio, United States

Cincinnati, Ohio, United States

Aberdeen, Washington, United States

Enumclaw, Washington, United States

Seattle, Washington, United States

Shelton, Washington, United States

Tacoma, Washington, United States

Yelm, Washington, United States

Carbondale, Illinois, United States

Carterville, Illinois, United States

Danville, Illinois, United States

Decatur, Illinois, United States

Effingham, Illinois, United States

Mattoon, Illinois, United States

New Lenox, Illinois, United States

O'fallon, Illinois, United States

Swansea, Illinois, United States

Yorkville, Illinois, United States

Louisville, Kentucky, United States

Brighton, Michigan, United States

Brownstown, Michigan, United States

Canton, Michigan, United States

Chelsea, Michigan, United States

Clinton Township, Michigan, United States

Novi, Michigan, United States

West Bloomfield, Michigan, United States

Ypsilanti, Michigan, United States

Maple Grove, Minnesota, United States

Wyoming, Minnesota, United States

Bonne Terre, Missouri, United States

Sainte Genevieve, Missouri, United States

Sullivan, Missouri, United States

Sunset Hills, Missouri, United States

Centerville, Ohio, United States

Cincinnati, Ohio, United States

Dayton, Ohio, United States

Findlay, Ohio, United States

Findlay, Ohio, United States

Franklin, Ohio, United States

Greenville, Ohio, United States

Kettering, Ohio, United States

Troy, Ohio, United States

Clackamas, Oregon, United States

Seattle, Washington, United States

Montvale, New Jersey, United States

Harrison, New York, United States

Uniondale, New York, United States

Middletown, New Jersey, United States

Dublin, California, United States

Ames, Iowa, United States

Boone, Iowa, United States

Fort Dodge, Iowa, United States

Jefferson, Iowa, United States

Marshalltown, Iowa, United States

Henderson, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Basking Ridge, New Jersey, United States

Clovis, California, United States

Walnut Creek, California, United States

Monticello, Minnesota, United States

Creve Coeur, Missouri, United States

Saint Louis, Missouri, United States

Carson City, Nevada, United States

Henderson, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Reno, Nevada, United States

Eau Claire, Wisconsin, United States

London, Kentucky, United States

Wexford, Pennsylvania, United States

Milwaukee, Wisconsin, United States

Kenner, Louisiana, United States

Mukwonago, Wisconsin, United States

Waukesha, Wisconsin, United States

Winchester, Massachusetts, United States

Westwood, Kansas, United States

Ashland, Wisconsin, United States

Gahanna, Ohio, United States

Phoenix, Arizona, United States

Orland Park, Illinois, United States

Fairway, Kansas, United States

Jefferson Hills, Pennsylvania, United States

Phoenix, Arizona, United States

San Luis Obispo, California, United States

Santa Maria, California, United States

Tawas City, Michigan, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Perrysburg, Ohio, United States

Buffalo, New York, United States

Metairie, Louisiana, United States

Seattle, Washington, United States

Fort Worth, Texas, United States

Henderson, Nevada, United States

Las Vegas, Nevada, United States

Pahrump, Nevada, United States

Beavercreek, Ohio, United States

Stevens Point, Wisconsin, United States

Johns Creek, Georgia, United States

Arroyo Grande, California, United States

Baton Rouge, Louisiana, United States

Springfield, Massachusetts, United States

Aitkin, Minnesota, United States

Deer River, Minnesota, United States

Hibbing, Minnesota, United States

Sandstone, Minnesota, United States

Virginia, Minnesota, United States

Hazleton, Pennsylvania, United States

Ashland, Wisconsin, United States

Metairie, Louisiana, United States

Ballwin, Missouri, United States

Washington, Missouri, United States

Newport Beach, California, United States

Port Huron, Michigan, United States

Bellevue, Nebraska, United States

Omaha, Nebraska, United States

Redmond, Oregon, United States

Burr Ridge, Illinois, United States

Lake Forest, Illinois, United States

Detroit Lakes, Minnesota, United States

Fosston, Minnesota, United States

Park Rapids, Minnesota, United States

Jamestown, North Dakota, United States

Springfield, Ohio, United States

Kingman, Arizona, United States

Dixon, Illinois, United States

Washington, Illinois, United States

Farmington, Missouri, United States

Henderson, Nevada, United States

Henderson, Nevada, United States

Henderson, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Peabody, Massachusetts, United States

Burnsville, Minnesota, United States

Bozeman, Montana, United States

Shelby, Michigan, United States

Cambridge, Minnesota, United States

Princeton, Minnesota, United States

Omaha, Nebraska, United States

Omaha, Nebraska, United States

Monroeville, Pennsylvania, United States

N. Huntingdon, Pennsylvania, United States

Richardson, Texas, United States

Cudahy, Wisconsin, United States

Frederick, Maryland, United States

Melrose Park, Illinois, United States

Homer Glen, Illinois, United States

Missoula, Montana, United States

Nampa, Idaho, United States

Alton, Illinois, United States

Springfield, Illinois, United States

Grand Island, Nebraska, United States

Perrysburg, Ohio, United States

Toledo, Ohio, United States

San Juan, , Puerto Rico

Shiloh, Illinois, United States

Mineola, New York, United States

Kansas City, Missouri, United States

Des Moines, Iowa, United States

Kalispell, Montana, United States

Dallas, Texas, United States

Troy, Ohio, United States

Nampa, Idaho, United States

Alcoa, Tennessee, United States

Pontiac, Michigan, United States

Pittsburg, Kansas, United States

Ann Arbor, Michigan, United States

Brighton, Michigan, United States

Chelsea, Michigan, United States

Danville, Illinois, United States

Boone, Iowa, United States

Fort Dodge, Iowa, United States

Jefferson, Iowa, United States

Marshalltown, Iowa, United States

Los Angeles, California, United States

Ames, Iowa, United States

Canton, Michigan, United States

Minocqua, Wisconsin, United States

Sunset Hills, Missouri, United States

Marysville, Ohio, United States

Clive, Iowa, United States

Lansing, Michigan, United States

Hays, Kansas, United States

Jefferson City, Missouri, United States

Pontiac, Michigan, United States

Silverdale, Washington, United States

Dayton, Ohio, United States

Sandpoint, Idaho, United States

Baker City, Oregon, United States

Ontario, Oregon, United States

Saginaw, Michigan, United States

Tawas City, Michigan, United States

Detroit, Michigan, United States

Grosse Pointe Woods, Michigan, United States

Grosse Pointe Woods, Michigan, United States

Macomb, Michigan, United States

Warren, Michigan, United States

Flint, Michigan, United States

Warren, Michigan, United States

East China Township, Michigan, United States

Macomb, Michigan, United States

Warren, Michigan, United States

Olathe, Kansas, United States

Grosse Pointe Woods, Michigan, United States

Rochester Hills, Michigan, United States

Mount Vernon, Illinois, United States

Clive, Iowa, United States

Des Moines, Iowa, United States

Denver, Colorado, United States

Rolla, Missouri, United States

Pittsburg, Kansas, United States

Littleton, Colorado, United States

Parker, Colorado, United States

Cape Girardeau, Missouri, United States

Winchester, Massachusetts, United States

Patients applied

0 patients applied

Trial Officials

Andrea B Apolo

Principal Investigator

Alliance for Clinical Trials in Oncology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials